

Press release, June 30, 2009

### **New share issue in Biovitrum AB (publ)**

In accordance with Biovitrum stock option program 2006:5 TO6 2006/2008, 400,778 new shares have been issued at the price SEK 59.00 per share, resulting in Biovitrum being provided funds of a total of SEK 23,645,902.00. There is no remaining stock options in the stock option program 2006:5 TO6 2006/2008.

After the share issue the outstanding number of shares in Biovitrum is 50,680,316.

### **For more information please contact:**

#### **Biovitrum**

Göran Arvidson, CFO  
Phone: +46 8 697 23 68

Erik Kinnman, VP Investor Relations  
Phone: +46 8 697 21 50  
[erik.kinnman@biovitrum.com](mailto:erik.kinnman@biovitrum.com)

### **About Biovitrum**

Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions globally. Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company has revenues of approximately SEK 1.2 billion and around 400 employees. The company head office is located in Sweden and it is listed on the Stockholm OMX Nordic Exchange. For more information please visit [www.biovitrum.com](http://www.biovitrum.com).

*Biovitrum AB (publ) may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on June 30, 2009 at 17:00 p.m. CET.*